Search Hotels in Sausalito

Amgen’s 17.6% return over the past six months has outpaced the S&P 500 by 6.3%, and its stock price has climbed to $328.43 per share. This was partly due to its solid quarterly results, and the...

Amgen (AMGN): Buy, Sell, or Hold Post Q3 Earnings?

December 30, 2025

As of late 2025, the global pharmaceutical landscape has undergone a tectonic shift, and at its center stands Eli Lilly and Company (NYSE: LLY). Once regarded as a steady, dividend-paying stalwart of...

Topics Stocks

The Trillion-Dollar Apothecary: Inside Eli Lilly’s Era of Metabolic Dominance

December 29, 2025

Companies with solid operating margins have a competitive edge, allowing them to reinvest for sustainable expansion. The best of these businesses balance profitability with reinvestment, setting...

Topics Earnings Economy Intellectual Property

3 Profitable Stocks with Competitive Advantages

December 28, 2025

As investors close the books on 2025, a year defined by the continued—yet tiring—dominance of artificial intelligence and mega-cap technology, the financial community is turning its gaze toward a...

Barking Back: Why the 'Dogs of the Dow' 4-Stock Play is the Contrarian Bet for 2026

December 25, 2025

Introduction As of December 25, 2025, the global pharmaceutical landscape is witnessing a seismic shift centered on a single Danish company: Novo Nordisk (NYSE: NVO). Long the undisputed king of the...

Topics Artificial Intelligence Economy Intellectual Property

The Oral Revolution: Novo Nordisk’s High-Stakes Bet on the Wegovy Pill

December 25, 2025

The Trillion-Dollar Pharma: A Deep Dive into Eli Lilly’s (LLY) Dominance in the Weight-Loss Era

Topics Economy Intellectual Property World Trade

December 25, 2025

As of December 25, 2025, the global pharmaceutical landscape has been fundamentally reshaped by a single entity: Eli Lilly and Company (NYSE: LLY). In a year defined by breakthrough medical treatments...

The Atomic Architect: How University of Washington’s Generative AI Just Rewrote the Rules of Medicine

Topics Economy Government Intellectual Property

December 24, 2025

In a milestone that many scientists once considered a "pipe dream" for the next decade, researchers at the University of Washington’s (UW) Institute for Protein Design (IPD) announced in late 2025 the...

Via TokenRing AI

Topics Artificial Intelligence

The Weight of Innovation: Eli Lilly’s Dominance in the GLP-1 Era

December 24, 2025

Date: December 24, 2025By: Financial Research Insights Introduction As 2025 draws to a close, few companies have dominated the financial and medical headlines as consistently as Eli Lilly and Company...

Fitch Sees Stable 2026 Outlook For Global Pharma — But Warns Trump Drug Pricing Push Poses Profit Risk ↗

Topics Economy

December 23, 2025

Via Stocktwits

Topics Government

SCHD vs. NOBL: Different Paths to Dividend Stability ↗

December 22, 2025

Both ETFs target dividend paying stocks, but their rules determine whether investors receive higher income or stricter dividend consistency

As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Biogen (NASDAQ:BIIB) and its peers.

Topics ETFs

Therapeutics Stocks Q3 In Review: Biogen (NASDAQ:BIIB) Vs Peers

December 21, 2025

Trump Strikes New Drug-Price Deals With Roche, Novartis, Merck And Other Pharma Giants ↗

Topics Artificial Intelligence

December 19, 2025

The deals expand the pricing program to most targeted drugmakers in exchange for temporary tariff relief.

Via Stocktwits

Topics Government World Trade

The Great Biotech Re-Shoring: Seres Therapeutics and the New Commodity-Driven Era

December 19, 2025

As the final weeks of 2025 unfold, the biotechnology sector is undergoing a fundamental transformation, shifting from a pure-play innovation market to one increasingly dictated by the "physical"...

This Is the 2nd Priciest Stock Market in 155 Years, Which Makes This High-Yield ETF a Genius Buy for 2026 ↗

Topics Earnings Economy Intellectual Property

December 19, 2025

This top-shelf exchange-traded fund (ETF) checks all the right boxes for income- and value-seeking investors.

As late 2025 draws to a close, a significant recalibration is underway in global financial markets, with investors increasingly rotating capital away from the once-dominant Big Tech and Artificial...

Topics Artificial Intelligence ETFs Economy

Investors Rotate Out of Big Tech and AI: A Market Reassessment Underway

December 17, 2025

Novartis US Stock Rises On Reports Of White House Pricing Deal Due Friday — Roche Also In Talks ↗

Topics Artificial Intelligence Economy Stocks

December 17, 2025

The potential agreements would mark another step in Washington’s broader effort to reshape drug pricing.

Via Stocktwits

Topics Government World Trade

Should You Buy the 5 Highest-Paying Dividend Stocks in the Dow Jones Before 2026? ↗

December 16, 2025

Each company has a bullish case, but three stand out as great long-term buys.

“Buying the Dip” in 2025: A Strategy Rewarded, But Future Requires Caution and Diversification

Topics Bonds Economy Intellectual Property

December 16, 2025

December 16, 2025 – The "buying the dip" investment strategy, which involves purchasing an asset after its price has declined with the anticipation of a subsequent recovery, has seen significant...

7 Dividend ETFs to Buy With $2,000 and Hold Forever -- Including the Schwab U.S. Dividend Equity ETF (SCHD) ↗

Topics Artificial Intelligence Economy

3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most ↗

December 16, 2025

Via MarketBeat

December 15, 2025

It's hard to beat dividend-paying stocks -- in part because they tend to increase their payouts regularly.

The Dow Jones (^DJI) is made up of 30 of the most established and influential companies in the market. But even blue-chip stocks can struggle - some are dealing with slowing growth, outdated business...

Topics ETFs

1 Dow Jones Stock Worth Your Attention and 2 We Brush Off

December 14, 2025

These dividend growth machines could have considerable upside for long-term investors.

Topics Stocks

2 Dividend Stocks to Double Up on Right Now ↗

December 14, 2025

The American labor market is experiencing a fascinating dichotomy as it navigates late 2024 and 2025. While overall job creation has shown signs of moderation and significant revisions to earlier...

Topics Economy Intellectual Property

Manufacturing Renaissance Fuels Job Market Amidst Shifting Sands

December 09, 2025

The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial...

Topics Artificial Intelligence Economy Electric Vehicles

2 Momentum Stocks for Long-Term Investors and 1 We Brush Off

December 07, 2025

Wondering which stocks are making significant price gaps? Explore the S&P500 index on Friday to find the gap up and gap down stocks in today's session.

Gapping S&P500 stocks in Friday's session ↗

December 05, 2025

Via Chartmill

3 Top ETFs I Plan to Pile Into in December to Boost My Passive Income in 2026 ↗

December 04, 2025

These ETFs can provide me with lots of passive income.

Shares crashed Tuesday on what one analyst called an "overreaction" to the company's prostate cancer treatment update.

Topics ETFs Stocks

Janux Therapeutics Craters 50% On Prostate Cancer Update; Is It An 'Overreaction'? ↗

December 02, 2025

Via Investor's Business Daily

2 Dividend Stocks to Double Up On Right Now ↗

December 01, 2025

Investors don't have to worry about dividend cuts with these two stocks.